FDA-cleared profile

CINA-ASPECTS

Avicenna.AI · CT/CTA · FDA-cleared (510(k))

Authorized purpose: CADx assistance for assessment and characterization of brain tissue abnormalities and early ischemic injury in patients with known MCA or ICA occlusion, using ASPECTS regions and scoring to evaluate extent of disease during image interpretation.

Clinical role
Post-acquisition NCCT preprocessing, tilt correction, predefined-ROI analysis, and automatic ASPECTS scoring; the clinician confirms the occlusion prerequisite, reviews and edits the result, and archives the final output.
Images and patients
CT/CTA · Brain, including ASPECTS regions
Key limitation
Keep in mind: Not intended for primary CT interpretation. It is validated and intended for known unilateral MCA or ICA occlusion, brain ischemia within 12 hours from last known well, patients over 21, and the listed Canon, GE, Philips, and Siemens scanner families. It is not suitable for tumors, abscesses, traumatic brain injury, hemorrhagic transformation, or hematoma; excessive motion, streak artifact, or significant noise can make scans technically inadequate.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: CADx assistance for assessment and characterization of brain tissue abnormalities and early ischemic injury in patients with known MCA or ICA occlusion, using ASPECTS regions and scoring to evaluate extent of disease during image interpretation.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain, including ASPECTS regions Input: Non-contrast head CT images in DICOM-compatible clinical imaging workflow from patients over 21 with known unilateral MCA or ICA occlusion, within 12 hours from time last known well, acquired on Canon, GE, Philips, or Siemens scanners; the clinician must confirm the LVO condition before results are available.
  • Who uses it?Intended users: Neuroradiologists and clinicians, including stroke neurologists, general radiologists, neurointensivists, and vascular neurologists.
  • What does the software produce?Output: An automatic ASPECTS score reflecting the number of affected regions, delineated and highlighted ASPECTS ROIs, a heat map of contributing voxels, region labels, underlying voxel values, and DICOM output for PACS or workstation review; the clinician can adjust the score.
  • What is its most important limitation?Key limitation: Not intended for primary CT interpretation. It is validated and intended for known unilateral MCA or ICA occlusion, brain ischemia within 12 hours from last known well, patients over 21, and the listed Canon, GE, Philips, and Siemens scanner families. It is not suitable for tumors, abscesses, traumatic brain injury, hemorrhagic transformation, or hematoma; excessive motion, streak artifact, or significant noise can make scans technically inadequate.

Clinical takeaway. Clinical role: CADx assistance for assessment and characterization of brain tissue abnormalities and early ischemic injury in patients with known MCA or ICA occlusion, using ASPECTS regions and scoring to evaluate extent of disease during image interpretation.

Evidence takeaway. Evidence from the reviewed source record: FDA standalone testing used a retrospective, multicenter, multinational, multi-vendor, blinded study of CINA-ASPECTS v1.5 with 200 anonymized NCCT cases from five sites in the US and France, four scanner makers, and 27 models; the dataset was separated from training/testing data. The MRMC study used eight readers, four expert neuroradiologists and four non-experts, each scoring 10 regions in the 200 cases. Readers agreed with almost one-half region more per scan with the device, 4.1% (95% CI 3.3%-4.9%); overall reader ROC AUC improved from 0.75 unaided to 0.79 aided, and mean time per case decreased. These are reader agreement, reader ROC, and workflow-time endpoints, not device sensitivity or specificity.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
CADx assistance for assessment and characterization of brain tissue abnormalities and early ischemic injury in patients with known MCA or ICA occlusion, using ASPECTS regions and scoring to evaluate extent of disease during image interpretation.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Post-acquisition NCCT preprocessing, tilt correction, predefined-ROI analysis, and automatic ASPECTS scoring; the clinician confirms the occlusion prerequisite, reviews and edits the result, and archives the final output.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Non-contrast head CT images in DICOM-compatible clinical imaging workflow from patients over 21 with known unilateral MCA or ICA occlusion, within 12 hours from time last known well, acquired on Canon, GE, Philips, or Siemens scanners; the clinician must confirm the LVO condition before results are available.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
An automatic ASPECTS score reflecting the number of affected regions, delineated and highlighted ASPECTS ROIs, a heat map of contributing voxels, region labels, underlying voxel values, and DICOM output for PACS or workstation review; the clinician can adjust the score.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Clinical or hospital environment operating in parallel with standard care.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Neuroradiologists and clinicians, including stroke neurologists, general radiologists, neurointensivists, and vascular neurologists.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Not intended for primary CT interpretation. It is validated and intended for known unilateral MCA or ICA occlusion, brain ischemia within 12 hours from last known well, patients over 21, and the listed Canon, GE, Philips, and Siemens scanner families. It is not suitable for tumors, abscesses, traumatic brain injury, hemorrhagic transformation, or hematoma; excessive motion, streak artifact, or significant noise can make scans technically inadequate.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA standalone testing used a retrospective, multicenter, multinational, multi-vendor, blinded study of CINA-ASPECTS v1.5 with 200 anonymized NCCT cases from five sites in the US and France, four scanner makers, and 27 models; the dataset was separated from training/testing data. The MRMC study used eight readers, four expert neuroradiologists and four non-experts, each scoring 10 regions in the 200 cases. Readers agreed with almost one-half region more per scan with the device, 4.1% (95% CI 3.3%-4.9%); overall reader ROC AUC improved from 0.75 unaided to 0.79 aided, and mean time per case decreased. These are reader agreement, reader ROC, and workflow-time endpoints, not device sensitivity or specificity.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA standalone testing used a retrospective, multicenter, multinational, multi-vendor, blinded study of CINA-ASPECTS v1.5 with 200 anonymized NCCT cases from five sites in the US and France, four scanner makers, and 27 models; the dataset was separated from training/testing data. The MRMC study used eight readers, four expert neuroradiologists and four non-experts, each scoring 10 regions in the 200 cases. Readers agreed with almost one-half region more per scan with the device, 4.1% (95% CI 3.3%-4.9%); overall reader ROC AUC improved from 0.75 unaided to 0.79 aided, and mean time per case decreased. These are reader agreement, reader ROC, and workflow-time endpoints, not device sensitivity or specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

CINA-ASPECTS regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K233342
  • Samplen=200
  • Sites5
  • IndependenceIndependence not established

K233342

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233342. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Non-contrast head CT images in DICOM-compatible clinical imaging workflow from patients over 21 with known unilateral MCA or ICA occlusion, within 12 hours from time last known well, acquired on Canon, GE, Philips, or Siemens scanners; the clinician must confirm the LVO condition before results are available.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K233342: CINA-ASPECTS

  2. Routing

    Source context, not route validation: A standalone executable can run from the command line or through medical image communications devices; it does not interface directly with CT scanners or data-collection equipment. Results are stored in DICOM for transfer to PACS or a workstation, with exact interface versions and local compatibility not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K233342: CINA-ASPECTS

  3. AI processing

    Source context, not route validation: The exact FDA package describes CINA-ASPECTS as a standalone executable program that may be run directly from the command line or through integration, deployment and use with medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "CINA-ASPECTS is a standalone executable program that may be run directly from the command-" … "line or through integration, deployment and use with medical image communications devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K233342: CINA-ASPECTS

  4. Returned objects

    Source context, not route validation: An automatic ASPECTS score reflecting the number of affected regions, delineated and highlighted ASPECTS ROIs, a heat map of contributing voxels, region labels, underlying voxel values, and DICOM output for PACS or workstation review; the clinician can adjust the score.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K233342: CINA-ASPECTS

  5. Viewer/worklist/report

    Unresolved route: An automatic ASPECTS score reflecting the number of affected regions, delineated and highlighted ASPECTS ROIs, a heat map of contributing voxels, region labels, underlying voxel values, and DICOM output for PACS or workstation review; the clinician can adjust the score.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K233342: CINA-ASPECTS

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes CINA-ASPECTS as a standalone executable program that may be run directly from the command line or through integration, deployment and use with medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "CINA-ASPECTS is a standalone executable program that may be run directly from the command-" … "line or through integration, deployment and use with medical image communications devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
A standalone executable can run from the command line or through medical image communications devices; it does not interface directly with CT scanners or data-collection equipment. Results are stored in DICOM for transfer to PACS or a workstation, with exact interface versions and local compatibility not established.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Avicenna.AI's cybersecurity page states ISO/IEC 27001 certification by SGS, IEC 81001-5-1, TLS 1.2+ in transit, encryption at rest, role-based access with least privilege, and a HIPAA business associate agreement for US customers. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

PACS and workstation are explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

Supported acquisition environment

Scanner manufacturers: Canon/Toshiba;GE;Philips;Siemens

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for CINA-ASPECTS; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K233342
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Brain, including ASPECTS regions
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-03-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
10Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K233342 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K233342: CINA-ASPECTS

    U.S. Food and Drug Administration - Published 2024-03-15 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. CINA-ASPECTS model card (K233342)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K233342

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Avicenna.AI Cybersecurity and Data Protection

    Avicenna.AI - Accessed 2026-10-25

    Scope: security

Research history

  1. K233342 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260729

Vascular Assist Occlusion Triage (VAOT) (v1.0)

GuideAI Health

Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support

Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Decision
2026-06-18
FDA-cleared K254075

Synapse Lung Nodule AI

Fujifilm Corporation

Authorized purpose: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.

Modality
CT/CTA
Anatomy
Chest/lungs; pulmonary nodules
Decision
2026-05-27
FDA-cleared K253520

Photonova Spectra, Photonova Spectra Select

Ge Medical Systems, LLC

Authorized purpose: Photonova Spectra and Spectra Select are silicon-based spectral photon-counting detector CT systems that acquire cross-sectional body images, multienergy data, monochromatic images, and material-density maps for labeled head, whole-body, cardiac, vascular, and lung workflows.

Modality
CT/CTA
Anatomy
Head, whole body, heart, vessels, and lungs
Decision
2026-03-20
FDA-cleared K260166

Bunkerhill Contrast CAC

BunkerHill Health

Authorized purpose: Detect, localize, and estimate the burden of coronary artery calcification on contrast-enhanced chest CT during clinical care.

Modality
CT/CTA
Anatomy
Chest/coronary arteries
Decision
2026-03-06

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history